AI-native drug development
We are rebuilding how drugs are developed around AI, from first principles, with people who have done it the old way for twenty years.
Most of that effort goes into biology, drug design and discovery. We work on development: the translational and clinical work that takes a molecule and makes it a drug.
Why development: a letter from our founderDevelopment has always optimized in that order, protecting one by spending the others. We believe that trade is no longer necessary. For the first time, all three can improve together.
Quality begins with the decision. When every relevant fact is in front of you and reasoned over at the moment you decide, you decide better. Fewer amendments, less rework and less lost time follow from that.
Nearly everything needed to make a better decision is freely available today: decades of trials, literature, real-world evidence, regulatory precedent. But no human team can retrieve it, weigh it, and apply it at the moment the decision is made. The limits are effort and cognition, not access. We're removing those limits, so every decision is made with everything that is known.
An enormous amount of energy, time, and resources disappears into inefficient tools, and into processes designed around those tools' limitations. Grafting better software onto old workflows only preserves the waste. We're rebuilding both at once: an entirely new way of working, built for what's possible now.
A new way of developing medicines is opening up, and what's possible today is a fraction of what will be possible next year. We aren't building for the current state of the art. We're building to keep pushing its limits, and to remain at the forefront as it moves.
Development starts before the first trial. What tissue, imaging, biology and earlier patients can tell you should shape the plan from the start. We do that translational work on the same platform as the clinical work, so what is learned in one reaches the other.
For the entire journey of a development program, translational and clinical, where today the work is spread across dozens of separate systems.
From the first translational question to the final submission, every step reads from and writes to the same living source of truth. It is built for regulated work from the first day: GxP by design, and ISO 27001 certified.
That's all we'll say for now.
Dizzaroo is built by people who have taken oncology programs from first-in-human through global approval, and by the engineers who work beside them. Here they are one team.
Drug development has long kept the people who know the medicine apart from the people who build its technology. AI closes that distance, because understanding the work is now most of building the tool. The roles are still different, but they have never been this close.
We think this is the form drug development will take: a fully integrated technology company. That is what we are building.
We are ready, and working with a small number of partners while we scale. If you are curious and want to work with us, write to us at office@dizzaroo.com.